Botulinum Toxin and Muscle Atrophy: A Wanted or Unwanted Effect.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms, clinical applications, and case reports without systematic review methodology.
PubMed 26780946 · doi:10.1093/asj/sjv208
What was done
The authors conducted a narrative review examining the mechanisms, intentional uses (body and facial contouring), and unintentional occurrences of botulinum toxin type A-induced muscle atrophy. They evaluated clinical reports of adverse atrophy (such as temporal wasting or hourglass deformity after migraine therapy and facial atrophy following treatment for hemifacial spasm), potential long-term effects, and the impact of repeated chemodenervation on treatment duration.
What was found
The abstract reports no quantitative data or specific sample sizes. The authors describe qualitative findings from the literature indicating that botulinum toxin-induced muscle atrophy is generally temporary and reversible following cessation of treatment. Additionally, they note that repeated treatments may prolong the duration of action over time, potentially reducing the required frequency of subsequent injections.
Why it matters
It clarifies that while muscle volume reduction can be leveraged cosmetically for body contouring, unintentional focal atrophy can also occur following therapeutic or aesthetic injections, reassuring clinicians that the atrophy typically resolves.
Limits
The paper is a non-systematic narrative review providing no quantitative synthesis, exact effect sizes, or formal risk of bias assessments. It relies partly on isolated case reports, and the abstract does not report specific patient counts, recovery timelines, or standardized criteria for assessing full functional and structural reversibility.
Cited by
- context Long-term use of Botox induces sarcopenia in facial muscles by intentionally breaking down the neuromuscular junction and atrophying the nerves.